selicrelumab (Roche)

Selicrelumab (also known as RO7009789, RG7876, or CP-870,893) is an investigational, fully human IgG2 agonistic monoclonal antibody that targets CD40 (tumor necrosis factor receptor superfamily member 5). CD40 is a key co-stimulatory molecule expressed on the surface of professional antigen-presenting cells (APCs), including dendritic cells, B cells, and macrophages. By binding to and activating CD40, selicrelumab mimics the signal provided by CD40 ligand (CD154), triggering APC maturation, upregulating costimulatory molecules (such as CD80 and CD86), and enhancing the production of pro-inflammatory cytokines like IL-12. This process, often termed 'licensing' of dendritic cells, facilitates the priming and expansion of tumor-specific cytotoxic CD8+ T cells, thereby promoting an effective anti-tumor immune response. Originally developed by Pfizer and subsequently licensed to Roche, selicrelumab is being evaluated in clinical trials for various malignancies, including pancreatic ductal adenocarcinoma, melanoma, and locally advanced rectal cancer, typically in combination with chemotherapy, radiotherapy, or other immunotherapies such as PD-L1 inhibitors.

Other names

anti-CD40 agonist antibodyanti-CD-40 agonist antibodyanti-CD 40 agonist antibodyCD40-agonistic monoclonal antibodyCD-40-agonistic monoclonal antibodyCD 40-agonistic monoclonal antibody